Axsome Therapeutics (AXSM) FCF Margin (2022 - 2026)

Axsome Therapeutics has disclosed FCF Margin across 5 years of filings, most recently posting 10.89% for Q1 2026.

• FCF Margin for Q1 2026 came in at 10.89%, up 2510.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.02% (up 2783.0% YoY), and the FY2025 annual result was 14.7%, up 1866.0% from the prior year.
• FCF Margin came in at 10.89% for Q1 2026 at Axsome Therapeutics, down from 9.55% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 0.58% in Q3 2025 to a low of 5246.4% in Q4 2024.
• The 5-year median for FCF Margin is 39.22% (2023), against an average of 396.3%.
• Across the five-year window, FCF Margin sank 520394 bps in 2024 and jumped 523685 bps in 2025, its largest moves.
• Axsome Therapeutics' FCF Margin stood at 113.84% in 2022, then surged by 63 bps to 42.46% in 2023, then sank by 12257 bps to 5246.4% in 2024, then jumped by 100 bps to 9.55% in 2025, then declined by 14 bps to 10.89% in 2026.
• The last three FCF Margin figures came in at 10.89% (Q1 2026), 9.55% (Q4 2025), and 0.58% (Q3 2025), per Business Quant data.